{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/69c6aa4bc2759aa9b124f8f4/6a3a96b4d1eb16a425a4b571?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Making the Medicine: Cheng Yi Chen on Scaling Drugs from Lab to Launch","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/69c6aa4bc2759aa9b124f8f4/1782224482828-e05b18cc-f82c-4e5d-a25e-3e7fb7de55c9.jpeg?height=200","description":"<p>It may seem obvious, but not all drugs are manufacturable. Getting an exciting new treatment from the lab to patients is only possible if the molecule or substance itself is scalable.&nbsp;</p><p><br></p><p>In this episode of<em> Dose of Discovery</em>, hosts Søren and AJ speak to Cheng Yi Chen, chief technology officer at Asymchem, about the chemistry, scaling up, and decision making behind moving a drug from clinical trials to commercial supply.</p><p><br></p><p>Cheng Yi shares the story of cancer drug adagrasib and the urgent supply challenge he faced at Mirati Therapeutics, when the original process couldn’t generate enough of the drug to support clinical trials.</p><p><br></p><p>Their conversation then turns to the broader world of process chemistry: how process routes are designed, the regulatory pathways they must follow, and sustainability issues they face.</p><p><br></p><p>They also discuss flow chemistry, continuous manufacturing, and why CDMOs play such an important role in helping new medicines reach patients – especially when it comes to dealing with regulators.</p><p><br></p><p>In this episode:</p><p><br></p><p><br></p><ul><li>03:48 – Explainer: What are CDMOs?</li><li>06:50 – Introducing Cheng Yi Chen</li><li>07:09 – The adagrasib supply challenge at Mirati</li><li>11:19 – How process chemistry enables clinical progress</li><li>16:57 – Moving between big pharma, biotech, and CDMOs work</li><li>27:06 – Peptides, oligos, and the rise of TIDES manufacturing</li><li>30:44 – Green chemistry, solvents, and cost-effective production</li><li>36:56 – Flow chemistry and continuous manufacturing</li><li>44:50 – Creating a manufacturing story for regulators</li><li>39:48 – China’s growing role in biotech innovation</li><li>47:57 – Wrap-up and key takeaways</li></ul><p><br></p><p><strong>About the guest</strong></p><p><br></p><p>Cheng Yi Chen is the chief technology officer at Asymchem. He has held senior process chemistry and drug development roles across Merck, Janssen, Mirati Therapeutics, and Bristol Myers Squibb. His work focuses on developing and manufacturing drug substances and products at scale.</p><p><br></p><p><em>Dose of Discovery</em> is cohosted by Søren Hough and Ayokunmi Ajetunmobi (AJ) and produced by Suze Cooper.</p><p><br></p><p><strong>LINKS:</strong></p><p><br></p><p><a href=\"https://www.bioxconomy.com/modalities/glp-1s-forced-industry-s-hand-on-sustainable-peptide-synthesis-says-expert\" rel=\"noopener noreferrer\" target=\"_blank\">GLP-1s forced industry’s hand on sustainable peptide synthesis, says expert</a> by Søren Hough (Interview with Fernando Albericio)&nbsp;</p><p><a href=\"https://www.bioxconomy.com/modalities/enzymes-open-door-simpler-efficient-oligo-synthesis\" rel=\"noopener noreferrer\" target=\"_blank\">Enzymes open the door for simpler, more efficient oligo therapeutic synthesis</a> by Søren Hough</p><p><a href=\"https://www.bioxconomy.com/modalities/adaptable-manufacturing-platforms-enable-in-vivo-mrna-lnp-delivery-says-lonza\" rel=\"noopener noreferrer\" target=\"_blank\">Adaptable manufacturing platforms enable in vivo mRNA-LNP delivery</a> by Søren Hough</p><p><a href=\"https://www.bioxconomy.com/modalities/industry-pioneers-solve-the-three-body-problem-of-rna-synthesis\" rel=\"noopener noreferrer\" target=\"_blank\">Industry pioneers solve the ‘three-body problem’ of RNA synthesis</a> by Søren Hough</p><p><a href=\"https://www.bioxconomy.com/modalities/eli-lilly-michael-kopach-retatrutide-leads-obesity-treatment-cmc-innovation\" rel=\"noopener noreferrer\" target=\"_blank\">Eli Lilly’s Michael Kopach says retatrutide leads in obesity treatment and CMC innovation</a> by Søren Hough</p><p><br></p><p>Read more at<a href=\"https://www.bioxconomy.com/modalities\" rel=\"noopener noreferrer\" target=\"_blank\"> <em>Bioxconomy</em></a>, sign up to our<a href=\"https://get.informaconnect.com/tides-newsletter-signup/\" rel=\"noopener noreferrer\" target=\"_blank\"> newsletter</a>, and don’t forget to check out our<a href=\"https://www.bioxconomy.com/events\" rel=\"noopener noreferrer\" target=\"_blank\"> upcoming events</a>.</p><p><br></p><p>You can find a fully annotated transcript of the episode <a href=\"https://www.bioxconomy.com/modalities/dose-of-discovery-cheng-yi-chen-on-scaling-drugs-from-lab-to-launch\" rel=\"noopener noreferrer\" target=\"_blank\">here</a>. </p>","author_name":"Søren Hough"}